Calcagno Pietro, Mazzola Michele, Forti Edoardo, Giani Alessandro, Zironda Andrea, Mucci Gaia, Paterno Michele, Mutignani Massimiliano, Ferrari Giovanni
Department of Oncologic and Minimally Invasive Surgery, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Digestive and Interventional Endoscopy Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore, 3, 20162, Milan, Italy.
Surg Endosc. 2025 Jul;39(7):4186-4194. doi: 10.1007/s00464-025-11786-2. Epub 2025 May 15.
Indications and outcomes of endoscopic approaches in treating postoperative pancreatic fistula (POPF) are underinvestigated. The present study aimed to evaluate the outcomes of patients undergoing endoscopic treatment for POPF following pancreaticoduodenectomy (PD).
Data of consecutive patients undergoing PD between 2014 and 2024 were retrospectively analyzed. Patients with POPF treated by an endoscopic approach were selected. The primary endpoint was clinical efficacy of the endoscopic approach. Secondary endpoints were variables associated with clinical efficacy of endoscopic treatment.
During the study period, a total of 436 patients underwent PD. Overall POPF rate was 18.4%. Twenty-one patients with POPF underwent endoscopic treatment and composed the study cohort. The median timing for endoscopic treatment was 20 postoperative days (POD). The types of endoscopic treatments performed included: trans-anastomotic intraductal pancreatic stent (23.8%); lumen apposing metal stent (LAMS) through the pancreatico-jejunal (PJ) anastomotic dehiscence (23.8%); large caliber aspirating nose-to-retroperitoneum tube through the PJ anastomosis leak (9.5%); triple metal stenting (enteral + biliary + pancreatic) (9.5%); transgastric LAMS close to pancreatic stump (14.3%); nose-to-retroperitoneum tube into a LAMS placed through PJ dehiscence (9.5%); transgastric LAMS near the pancreatic stump associated with an intraductal pancreatic trans-anastomotic stent (9.5%). Technical and clinical success rate were 100% and 71.4%, respectively. After endoscopic treatment, 19% of patients underwent surgical reoperation and 9.5% died. Timing of endoscopic treatment was the only factor associated with clinical success (POD 20 vs POD 13.5; p = 0.039).
Endoscopy can be an effective option for managing POPF after PD with a clinical success rate of 71.4%. Proper patient selection and the timing of intervention are key to achieving good clinical outcomes. Higher success rate was seen for endoscopic treatment performed after the 20th POD.
内镜治疗术后胰瘘(POPF)的适应证和疗效尚未得到充分研究。本研究旨在评估胰十二指肠切除术(PD)后接受内镜治疗POPF患者的疗效。
回顾性分析2014年至2024年间连续接受PD治疗患者的数据。选择采用内镜治疗的POPF患者。主要终点是内镜治疗的临床疗效。次要终点是与内镜治疗临床疗效相关的变量。
在研究期间,共有436例患者接受了PD治疗。总体POPF发生率为18.4%。21例POPF患者接受了内镜治疗,组成了研究队列。内镜治疗的中位时间为术后20天(POD)。所进行的内镜治疗类型包括:经吻合口胰管内支架置入(23.8%);通过胰肠(PJ)吻合口裂开处放置管腔贴附金属支架(LAMS)(23.8%);通过PJ吻合口漏口置入大口径经鼻至腹膜后的吸引管(9.5%);三重金属支架置入(肠内+胆管+胰管)(9.5%);经胃靠近胰腺残端置入LAMS(14.3%);经鼻至腹膜后的引流管置入通过PJ吻合口裂开处放置的LAMS内(9.5%);经胃靠近胰腺残端置入LAMS并联合经吻合口胰管内支架置入(9.5%)。技术成功率和临床成功率分别为100%和71.4%。内镜治疗后,19%的患者接受了再次手术,9.5%的患者死亡。内镜治疗时间是与临床成功相关的唯一因素(POD 20天与POD 13.5天;p = 0.039)。
内镜检查可作为PD后治疗POPF的有效选择,临床成功率为71.4%。正确选择患者和干预时机是取得良好临床效果的关键。术后第20天之后进行内镜治疗的成功率更高。